Cue Biopharma Inc (CUE)
NASDAQ:CUE
US Market
Holding CUE?
Track your performance easily

Cue Biopharma (CUE) Income Statement

580 Followers

Cue Biopharma Income Statement

Last quarter (Q2 2024), Cue Biopharma's total revenue was $2.66M, an increase of 1321.39% from the same quarter last year. In Q2, Cue Biopharma's net income was $-10.17M. See Cue Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 7.86M$ 5.49M$ 1.25M$ 14.94M$ 3.15M$ 3.46M
Cost of Revenue
------
Gross Profit
$ 7.86M$ 5.49M$ 1.25M$ 14.94M$ 3.15M$ 3.46M
Operating Expense
$ 55.84M$ 57.48M$ 54.75M$ 58.65M$ 48.20M$ -40.23M
Operating Income
$ -47.99M$ -52.15M$ -53.78M$ -43.71M$ -45.04M$ -36.77M
Net Non Operating Interest Income Expense
$ 1.28M$ 1.42M$ -215.00K$ 45.90K$ 463.91K$ 482.79K
Other Income Expense
-$ -157.00K$ 277.00K$ -7.13K$ -17.45K$ -637.00
Pretax Income
$ -46.71M$ -50.73M$ -53.01M$ -43.67M$ -44.58M$ -36.29M
Tax Provision
---$ 495.00K$ 206.25K$ 412.50K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -46.71M$ -50.73M$ -53.01M$ -44.16M$ -44.78M$ -36.70M
Basic EPS
$ -0.98$ -1.11$ -1.49$ -1.41$ -1.56-
Diluted EPS
$ -0.98$ -1.11$ -1.49$ -1.41$ -1.56$ -1.66
Basic Average Shares
$ 190.80M$ 45.75M$ 35.65M$ 31.29M$ 28.69M$ 22.04M
Diluted Average Shares
$ 190.80M$ 45.75M$ 35.65M$ 31.29M$ 28.69M$ 22.11M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 55.84M$ 57.48M$ 54.75M$ 58.65M$ 48.20M$ -40.23M
Net Income From Continuing And Discontinued Operation
$ -46.71M$ -50.73M$ -53.01M$ -44.16M$ -44.78M$ -36.70M
Normalized Income
$ -30.99M--$ -34.50M--
Interest Expense
------
EBIT
$ -45.73M$ -49.49M$ -52.30M$ -43.67M$ -45.04M$ -36.29M
EBITDA
$ -44.59M$ -49.13M$ -50.49M$ -43.67M$ -45.04M$ -35.55M
Currency in USD

Cue Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis